UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have been given a consensus recommendation of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $35.67.

A number of equities research analysts recently commented on URGN shares. Scotiabank began coverage on UroGen Pharma in a research report on Wednesday. They issued a “sector outperform” rating and a $23.00 price target for the company. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. HC Wainwright cut their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new stake in shares of UroGen Pharma during the fourth quarter worth $59,000. Lazard Asset Management LLC bought a new stake in shares of UroGen Pharma during the 4th quarter valued at $67,000. GAMMA Investing LLC lifted its holdings in UroGen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock worth $83,000 after purchasing an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC bought a new position in UroGen Pharma in the 4th quarter worth about $101,000. Finally, BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after buying an additional 5,890 shares in the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

UroGen Pharma Stock Down 3.3 %

Shares of NASDAQ URGN opened at $10.39 on Thursday. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The company has a 50-day moving average price of $10.52 and a 200-day moving average price of $11.23. The stock has a market capitalization of $478.92 million, a P/E ratio of -3.30 and a beta of 0.80. UroGen Pharma has a 1 year low of $8.94 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. On average, equities research analysts forecast that UroGen Pharma will post -3.12 EPS for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.